Colorectal Cancer

Metastatic Colorectal Cancer

Nadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center (ICPC), Tel Aviv Sourasky Medical Center, discusses prevention and screening of colorectal cancer (CRC).

Halfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.

Results of a large expanded access program, presented at the 2015 World Congress on GI Cancer, confirmed the efficiency and safety of regorafenib (Stivarga) in previously treated patients with mCRC.

Guy Van Hazel, MD, Medical Oncologist, Mount Hospital and School of Medicine University of Western Australia, discusses the effects of selective internal radiation therapy (SIRT) and bevacizumab on extrahepatic colorectal cancer (CRC) metastases.

Luis Alberto Diaz, Jr, MD, associate professor of Oncology, Johns Hopkins University, discusses PD-1 blockade in mismatch repair deficiency in colorectal cancer (CRC).

The survival benefit observed with regorafenib over placebo in Asian patients who had been previously treated for mCRC in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

Metastatic CRC with Marwan G. Fakih, MD and Tanios Bekaii-Saab, MD

Metastatic CRC with Marwan G. Fakih, MD and Tanios Bekaii-Saab, MD

Reactivation of the tumor suppressor gene adenomatous polyposis coli (Apc) reverted colorectal cancer cells back to normal intestinal tissue in mice, according to a recent preclinical study.